Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
Open Access
- 1 June 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Vascular Health and Risk Management
- Vol. 7, 405-16
- https://doi.org/10.2147/VHRM.S20737
Abstract
Peer reviewed article authored by (Mason RP). Read article or submit your manuscript for publishing.Keywords
This publication has 75 references indexed in Scilit:
- Nitric Oxide Mechanisms in the Pathogenesis of Global RiskThe Journal of Clinical Hypertension, 2006
- Effects of Angiotensin II Receptor Blockade with Valsartan on Pro-Inflammatory Cytokines in Patients with Essential HypertensionJournal of Cardiovascular Pharmacology, 2005
- Effect of Atorvastatin and Irbesartan, Alone and in Combination, on Postprandial Endothelial Dysfunction, Oxidative Stress, and Inflammation in Type 2 Diabetic PatientsCirculation, 2005
- Endothelial function and dysfunction. Part IJournal of Hypertension, 2005
- Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With MicroinflammationCirculation, 2004
- Reactive oxygen species in vascular biology: implications in hypertensionHistochemistry and Cell Biology, 2004
- Clinical efficacy and tolerability of olmesartanClinical Therapeutics, 2004
- Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor-κB, in Mononuclear Cells of Normal Subjects: Evidence of an Antiinflammatory ActionJournal of Clinical Endocrinology & Metabolism, 2003
- The pathogenesis of atherosclerosis and new opportunities for treatment and preventionPublished by Springer Science and Business Media LLC ,2002
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsThe New England Journal of Medicine, 2000